Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
GLAUKOS Corp director Denice Torres reported a stock option grant and corrected prior disclosure details. She received options for 2,987 shares of common stock at an exercise price of $106.52 per share, granted under the issuer's Director Compensation Policy. The options vest in full on the one-year anniversary of the May 28, 2026 grant date and expire on May 28, 2036. This Form 4/A also amends a prior Form 4 that mistakenly reported the exercise price as $53.57, clarifying that the correct exercise price is $106.52.
Glaukos Corp’s chief development officer Tomas Navratil sold 1,537 shares of common stock in an open-market trade. The sale was executed at an average price of $130.68 per share under a Rule 10b5-1 trading plan adopted on March 12, 2026.
After this transaction, he directly holds 88,833 shares of Glaukos common stock, which includes 39,791 restricted stock units that have not yet vested or been delivered.
Glaukos Corporation submitted a Form 144 notice regarding proposed sales of Common Stock tied to restricted stock vesting and recent dispositions. The filing lists restricted stock vesting entries of 259 shares (11/15/2024), 153 shares (12/13/2024) and 1,125 shares (03/24/2025). It also records recent sales by Tomas Navratil, including 1,031 shares on 03/16/2026 and 2,093 shares on 04/10/2026.
Glaukos Corporation held its annual stockholder meeting and reported voting results on three proposals. Stockholders elected Class II directors Denice M. Torres and Aimee S. Weisner to serve until the 2029 annual meeting, with Weisner receiving 49,397,952 votes for and Torres 40,843,317 votes for. The advisory vote on executive compensation passed, with 47,653,794 votes for and 4,272,830 against. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 54,476,088 votes for and 515,703 against.
GLAUKOS Corp director Leana Wen reported receiving equity compensation on May 28, 2026. She was granted 1,878 restricted stock units under the company’s Director Compensation Policy; these units vest in full one year after the grant and will be settled in an equal number of common shares.
She also received a stock option for 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. After these awards, Wen directly holds 21,617 shares of common stock, which the filing notes include previously granted restricted stock units that are unvested or deferred.
GLAUKOS Corp director Aimee S. Weisner received new equity compensation awards. On May 28, 2026, she was granted 1,878 restricted stock units under the company’s Director Compensation Policy. These units vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of common shares.
She was also granted 2,987 stock options with an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. Following these awards, she holds 20,684 common shares directly, in addition to indirect holdings of 2,000 shares through the Weisner Saeman Family Irrevocable Trust and 29,505 shares through the Saeman-Weisner Family Trust. These are compensation-related grants rather than open-market purchases or sales.
GLAUKOS Corp director Denice Torres reported equity awards as part of standard board compensation. She received 1,878 restricted stock units that will vest in full on the one-year anniversary of the grant date and convert into the same number of common shares. She was also granted stock options for 2,987 shares of common stock with an exercise price of $53.57 per share, vesting in full after one year and expiring in 2036. Following these grants, she directly holds 24,212 shares of common stock, which include 4,609 restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp director Mark J. Foley received equity compensation consisting of new restricted stock units and stock options. He was granted 1,878 restricted stock units under the company’s Director Compensation Policy, which will vest in full on the one-year anniversary of the grant date and then convert into the same number of common shares.
Foley was also granted stock options covering 2,987 shares of common stock with an exercise price of $53.57 per share, also vesting in full one year after the grant date and expiring in 2036. After these awards, he directly holds 60,267 shares of common stock, including 5,154 restricted stock units that have not yet vested or been delivered, highlighting this filing as a routine, compensation-related acquisition rather than an open-market purchase or sale.
GLAUKOS Corp director David F. Hoffmeister reported equity compensation awards. He received 1,878 restricted stock units under the company’s Director Compensation Policy, which vest in full on the one-year anniversary of the May 28 grant and are payable in the same number of common shares.
He also received stock options for 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full after one year and expiring on May 28, 2036. Following these awards, he holds 49,549 shares directly, including 4,739 unvested or deferred restricted stock units, and 38,176 shares indirectly through Sentinel Point Partners, Inc.
GLAUKOS Corp director Gilbert H. Kliman received new equity awards as part of the company’s director compensation program. He was granted 1,878 shares of common stock in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and will be settled in an equal number of shares.
He also received a stock option for 2,987 shares of common stock with an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. After these awards, Kliman directly holds 37,406 shares of common stock. Footnote disclosure states this total includes 4,609 restricted stock units that are either unvested or vested but with delivery deferred.